A new oral #MSdrug on the scene

Nerve - for MS

After Merck KGaA was forced to pull the Cladribine program it has partnered with Japan's Ono Pharmaceuticals. A new release showed the oral MS drug in the partnership, ONO-4641, eliminated a large percentage of brain lesions which are associated with the disease. The study recruited 407 patients and after 26 weeks of a daily dose, investigators found that the mid-range dose had eliminated 92% of the brain lesions compared to the placebo. Although there appears to be cardiovascular issues as well as liver enzyme elevation, the MS drug showed some promising results and now faces the stiff competition from other developers Biogen Idec's BG-12 – among them and Teva Pharmaceuticals laquinimod pill.

Leave a Reply

Your email address will not be published. Required fields are marked *